stockrowBeOne Medicines Ltd. - Sponsored ADR
BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024.
- Revenue
- +33.8%
- EPS
- +143.7%
- Free cash flow
- +33.6%
- Total debt
- +491.3%
Quarter to September 2026, against a year earlier
Follow ONC
Alert me
BeOne Medicines Ltd. - Sponsored ADR (ONC) Return on invested capital
BeOne Medicines Ltd. - Sponsored ADR's return on invested capital over the twelve months to 30 September 2026 was 85.2%, up 49.2 percentage points from fiscal 2025 (36.0%). Over the past ten years it has ranged from −3,627.3% (fiscal 2016) to 36.0% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 36.0% | 76.79 |
| FY2024 | −40.8% | 93.28 |
| FY2023 | −134.0% | 155.39 |
| FY2022 | −289.4% | 252.46 |
| FY2021 | −541.9% | (541.89) |
| FY2020 | 0.00% | 243.08 |
| FY2019 | −243.1% | 39.58 |
| FY2018 | −282.7% | 255.71 |
| FY2017 | −538.4% | 3,088.92 |
| FY2016 | −3,627.3% | (3,627.29) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ONC BeOne Medicines Ltd. - Sponsored ADR | 85.2% |
| INCY Incyte Corporation compare | 21.6% |
| GMAB Genmab A/S Sponsored ADR compare | 6.99% |
| RPRX Royalty Pharma PLC compare | 5.24% |
| RVMD Revolution Medicines, Inc. compare | 0.00% |
| ARGX argenex SE compare | 0.00% |
| BNTX BioNTech SE Sponsored ADR compare | −34.3% |
| ROIV Roivant Sciences Ltd. compare | −34.5% |
| INSM Insmed, Inc. compare | −247.6% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on ONC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement